Pharming amends Ruconest distribution deal with SOBI

14 July 2016

Netherlands-based Pharming Group (Euronext: PHARM) and rare diseases specialist Swedish Orphan Biovitrum (STO: SOBI) have amended their Ruconest distribution agreement signed in 2009. Ruconest (recombinant human C1 inhibitor) is a treatment for acute attacks of hereditary angioedema (HAE)

In addition to Austria, Germany and Netherlands, Pharming will market Ruconest directly into an additional 21 countries, effective October 1, 2016. These countries include Algeria, Andorra, Bahrain, Belgium, France, Ireland, Jordan, Kuwait, Lebanon, Luxembourg, Morocco, Oman, Portugal, Qatar, Syria, Spain, Switzerland, Tunisia, United Arab Emirates, UK and Yemen

To support the commercialization, Pharming will expand the current small European team of experienced HAE marketing and medical affairs specialists. To ensure a seamless hand-over and guarantee the continuous availability of Ruconest to patients, SOBI will continue to deliver Ruconest and continue the drug safety monitoring and reporting, until October 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK